F-598 is under clinical development by Alopexx and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect F-598’s likelihood of approval (LoA) and phase transition for Hospital-Acquired Infections took place on 04 Nov 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their F-598 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
F598 (SAR-279356) is under development for the treatment of poly-N-acetylglucosamine (PNAG) infections, S. pneumoniae-induced Pneumonia, gram-negative bacterial infections, hospital-acquired infections, gram-positive bacterial infections, fungal infections, pulmonary tuberculosis and for the prevention of infection after emergency abdominal surgery or abdominal trauma. The therapeutic candidate binds to a conserved surface polysaccharide known as poly-N-acetyl glucosamine (PNAG). F598 is a fully human monoclonal antibody. The drug is administered through intravenous infusion. It was under development for prevention and treatment of serious bacterial infections like gonorrhea in intensive care unit (ICU) patients on mechanical ventilation.
Alopexx is a clinical stage biotechnology company focusing on developing novel, broad-spectrum immune-mediated therapeutics. Alopexx is headquartered in Cambridge, Massachusetts, the US.
Quick View F-598 LOA Data
|Highest Development Stage|